The latest price target for Vistagen Therapeutics (NASDAQ:VTGN) was reported by William Blair on December 17, 2025. The analyst firm set a price target for $0.00 expecting VTGN to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Vistagen Therapeutics (NASDAQ:VTGN) was provided by William Blair, and Vistagen Therapeutics downgraded their market perform rating.

The last upgrade for Vistagen Therapeutics Inc happened on December 7, 2023 when Jefferies raised their price target to $15. Jefferies previously had a hold for Vistagen Therapeutics Inc.

The last downgrade for Vistagen Therapeutics Inc happened on December 17, 2025 when William Blair changed their price target from N/A to N/A for Vistagen Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vistagen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vistagen Therapeutics was filed on December 17, 2025 so you should expect the next rating to be made available sometime around December 17, 2026.

While ratings are subjective and will change, the latest Vistagen Therapeutics (VTGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Vistagen Therapeutics (VTGN) is trading at is $0.82, which is out of the analyst’s predicted range.